ProCE Banner Activity

Pneumococcal Vaccination: A Global Challenge in Coverage and Serotype Protection

Clinical Thought

New data from ID Week 2024 emphasize that although surveillance of pneumococcal serotype distribution can help with the optimal selection of pneumococcal vaccines, vaccination coverage remains low, even among patients with prior episodes of invasive pneumococcal disease.

Released: December 23, 2024

Expiration: December 22, 2025

Share

Faculty

Elisabeth Botelho-Nevers

Elisabeth Botelho-Nevers, MD, PhD, HDR

Full Professor in Infectious Diseases
Head of Infectious Disease Department
University Hospital Saint-Etienne
CIRI Lab, Team GIMAP, Inserm, U1111, CNRS, UMR530
Chair Prevention, Vaccination, Controle de l’infection - PRESAGE
University of Saint-Etienne
Saint-Etienne, France

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Merck & Co., Inc., Rahway, NJ, USA

Disclosure

Primary Author

Elisabeth Botelho-Nevers, MD, PhD, HDR

Full Professor in Infectious Diseases
Head of Infectious Disease Department
University Hospital Saint-Etienne
CIRI Lab, Team GIMAP, Inserm, U1111, CNRS, UMR530
Chair Prevention, Vaccination, Controle de l’infection - PRESAGE
University of Saint-Etienne
Saint-Etienne, France

Elisabeth Botelho-Nevers, MD, PhD, HDR: consultant/advisor/speaker: GlaxoSmithKline, Merck Sharp & Dohme, Moderna, Pfizer, Sanofi Pasteur; researcher: GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Moderna, Pfizer, Sanofi Pasteur.